Literature DB >> 25755160

Osteosarcoma in patients younger than 12 years old without metastases have similar prognosis as adolescent and young adults.

Sabrina Jeane Prates Eleutério1, Andreza Almeida Senerchia1, Maria Teresa Almeida2, Cecilia Maria Da Costa3, Daniel Lustosa4, Luiz Mario Calheiros5, Jose Henrique Silva Barreto6, Algemir Lunardi Brunetto7, Carla Renata Pacheco Donato Macedo1, Antonio Sergio Petrilli1.   

Abstract

BACKGROUND: Childhood cancer is relatively rare and tends to present specific age distribution, as a prognostic factor for some of these diseases. Information on how young age affects prognosis, response to chemotherapy, and local control options in children versus AYA with osteosarcoma (OST) is minimal.
METHODS: In order to identify the main differences in clinical pathologic features, surgical approaches and survival rates of primary high grade OST of the extremity between children (n = 156; <12 years old) and AYA (n = 397; 12-30 years old), the institutional database with 553 patients treated by BOTG studies over 15 years were reviewed.
RESULTS: There were no differences in metastases at diagnosis, tumor size, and grade of necrosis between the two age groups. The rate of amputation was 30% higher in the children group (P = 0.018). The rate of limb salvage surgery using reconstruction with allograft or autograft was 70% higher in the children group (P = 0.018) while endoprosthesis rate was 40% higher in the AYA group (P = 0.018). The log rank test revealed that survival is similar between the two age groups for non-metastatic patients (P = 0.424 for OS and P = 0.393 for EFS). Metastatic patients of both ages group had higher risk of dying compared to non-metastatic (HR 3.283 95% CI 2.581-4.177; P < 0.001). Children with metastases at diagnosis had less OS time (P = 0.049) and EFS time (P = 0.032) than adolescents.
CONCLUSION: Non-metastatic OST in preadolescent patients does not appear to be significantly different from those seen in AYA patients, but has local control challenges. Children presenting with metastases should be considered an ultra-high-risk group.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  adolescent; amputation; chemotherapy; childhood bone cancer; children; osteosarcoma; young adult

Mesh:

Year:  2015        PMID: 25755160     DOI: 10.1002/pbc.25459

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  14 in total

1.  MicroRNA-34a promotes cell cycle arrest and apoptosis and suppresses cell adhesion by targeting DUSP1 in osteosarcoma.

Authors:  Liu Gang; Li Qun; Wei-Dong Liu; Yong-Sheng Li; Yao-Zeng Xu; Dong-Tang Yuan
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  What Are the Complications of Allograft Reconstructions for Sarcoma Resection in Children Younger Than 10 Years at Long-term Followup?

Authors:  Luis A Aponte-Tinao; Jose I Albergo; Miguel A Ayerza; D Luis Muscolo; Federico Milano Ing; German L Farfalli
Journal:  Clin Orthop Relat Res       Date:  2018-03       Impact factor: 4.176

3.  Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan.

Authors:  Takashi Fukushima; Koichi Ogura; Toru Akiyama; Katsushi Takeshita; Akira Kawai
Journal:  BMC Musculoskelet Disord       Date:  2018-08-18       Impact factor: 2.362

4.  Incidence and mortality of bone cancer among children, adolescents and young adults of Brazil.

Authors:  Nathalie Vieira Balmant; Rejane de Souza Reis; Marceli de Oliveira Santos; Mariana Maschietto; Beatriz de Camargo
Journal:  Clinics (Sao Paulo)       Date:  2019-05-13       Impact factor: 2.365

5.  The proliferation and invasion of osteosarcoma are inhibited by miR-101 via targetting ZEB2.

Authors:  Haopeng Lin; Xiaodong Zheng; Ting Lu; Yang Gu; Canhao Zheng; Huajie Yan
Journal:  Biosci Rep       Date:  2019-02-08       Impact factor: 3.840

6.  miR-451a Inhibits the Growth and Invasion of Osteosarcoma via Targeting TRIM66.

Authors:  Xiao Ma; Dan Li; Yan Gao; Cheng Liu
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

7.  miR-34 inhibits growth and promotes apoptosis of osteosarcoma in nude mice through targetly regulating TGIF2 expression.

Authors:  Liang Xi; Yongfeng Zhang; Shengnan Kong; Wei Liang
Journal:  Biosci Rep       Date:  2018-06-12       Impact factor: 3.840

8.  Treatment of osteosarcoma around the knee in skeletally immature patients.

Authors:  Weitao Yao; Qiqing Cai; Jiaqiang Wang; Songtao Gao
Journal:  Oncol Lett       Date:  2017-09-06       Impact factor: 2.967

9.  Clinical features and outcomes of primary bone and soft tissue sarcomas in adolescents and young adults.

Authors:  Kazuhiko Hashimoto; Shunji Nishimura; Naohiro Oka; Masao Akagi
Journal:  Mol Clin Oncol       Date:  2020-02-04

10.  Prognostic factors in osteosarcoma: A study level meta-analysis and systematic review of current practice.

Authors:  Sun Xin; Guo Wei
Journal:  J Bone Oncol       Date:  2020-02-21       Impact factor: 4.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.